Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.

Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Calcif Tissue Int. 2018 Oct 20. doi: 10.1007/s00223-018-0485-2. [Epub ahead of print]

PMID:
30343436
2.

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry.

Winthrop KL, Saag K, Cascino MD, Pei J, John A, Jahreis A, Haselkorn T, Furst DE.

Arthritis Care Res (Hoboken). 2018 Oct 8. doi: 10.1002/acr.23781. [Epub ahead of print]

PMID:
30295434
3.

The prevalence of overtreatment of osteoporosis: results from the PAADRN trial.

Hall SF, Wright NC, Wolinsky FD, Lou Y, Edmonds S, Roblin D, Jones M, Saag K, Cram P.

Arch Osteoporos. 2018 Sep 28;13(1):103. doi: 10.1007/s11657-018-0517-6.

PMID:
30267162
4.

Moving Career Development Upstream: Evaluation of a Course for Internal Medicine Trainees Contemplating Career Pathways in Academic Medicine.

Kraemer RR, Wakelee JF, Hites L, Frank SJ, Saag K, Rogers DA, Nellore A, Erdmann N, Nichols AC, Merlin JS.

South Med J. 2018 Aug;111(8):471-475. doi: 10.14423/SMJ.0000000000000844.

PMID:
30075472
5.

Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.

Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Bone. 2018 Nov;116:58-66. doi: 10.1016/j.bone.2018.07.013. Epub 2018 Jul 18.

PMID:
30021126
6.

Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.

Balasubramanian A, Wade SW, Adler RA, Saag K, Pannacciulli N, Curtis JR.

J Bone Miner Res. 2018 Oct;33(10):1881-1888. doi: 10.1002/jbmr.3523. Epub 2018 Aug 22.

PMID:
29924418
7.

Efficacy and safety of febuxostat extended release and immediate release in patients with gout and moderate renal impairment: phase II placebo-controlled study.

Gunawardhana L, Becker MA, Whelton A, Hunt B, Castillo M, Saag K.

Arthritis Res Ther. 2018 May 30;20(1):99. doi: 10.1186/s13075-018-1593-0.

8.

Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study.

Tausche AK, Alten R, Dalbeth N, Kopicko J, Fung M, Adler S, Bhakta N, Storgard C, Baumgartner S, Saag K.

Rheumatology (Oxford). 2017 Dec 1;56(12):2170-2178. doi: 10.1093/rheumatology/kex350.

PMID:
29029210
9.

Development and Pilot Testing of Multimedia Patient Education Tools for Patients With Knee Osteoarthritis, Osteoporosis, and Rheumatoid Arthritis.

Lopez-Olivo MA, Ingleshwar A, Volk RJ, Jibaja-Weiss M, Barbo A, Saag K, Leong A, Suarez-Almazor ME.

Arthritis Care Res (Hoboken). 2018 Feb;70(2):213-220. doi: 10.1002/acr.23271. Epub 2017 Dec 29.

PMID:
28464546
10.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

11.

Cost-effectiveness of Low-dose Submicron Diclofenac Compared With Generic Diclofenac.

Mladsi D, Ronquest N, Odom D, Miles L, Saag K.

Clin Ther. 2016 Nov;38(11):2418-2429. doi: 10.1016/j.clinthera.2016.09.013. Epub 2016 Oct 26.

PMID:
27793353
12.

Treat-to-target (T2T) recommendations for gout.

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J.

Ann Rheum Dis. 2017 Apr;76(4):632-638. doi: 10.1136/annrheumdis-2016-209467. Epub 2016 Sep 22.

PMID:
27658678
13.

Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients.

Mannion ML, Xie F, Baddley J, Chen L, Curtis JR, Saag K, Zhang J, Beukelman T.

Pediatr Rheumatol Online J. 2016 Sep 5;14(1):49. doi: 10.1186/s12969-016-0107-3.

14.

Reply.

Saag K, Gunawardhana L.

Arthritis Rheumatol. 2016 Oct;68(10):2564. doi: 10.1002/art.39768. No abstract available.

15.

Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis.

Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR.

Osteoporos Int. 2016 Nov;27(11):3239-3249. doi: 10.1007/s00198-016-3646-z. Epub 2016 Jun 8.

PMID:
27273113
16.

Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.

Zhang J, Xie F, Yun H, Chen L, Muntner P, Levitan EB, Safford MM, Kent ST, Osterman MT, Lewis JD, Saag K, Singh JA, Curtis JR.

Ann Rheum Dis. 2016 Oct;75(10):1813-8. doi: 10.1136/annrheumdis-2015-207870. Epub 2016 Jan 20.

PMID:
26792814
17.

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Cooper C, Bardin T, Brandi ML, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W, Devogelaer JP, Diez-Perez A, Einhorn TA, Emonts P, Ethgen O, Kanis JA, Kaufman JM, Kvien TK, Lems WF, McCloskey E, Miossec P, Reiter S, Ringe J, Rizzoli R, Saag K, Reginster JY.

Aging Clin Exp Res. 2016 Feb;28(1):1-16. doi: 10.1007/s40520-015-0522-1. Epub 2016 Jan 8. Review.

PMID:
26746234
18.

2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vaquez-Mellado J, Yarows SA, Taylor WJ.

Ann Rheum Dis. 2015 Oct;74(10):1789-98. doi: 10.1136/annrheumdis-2015-208237. Erratum in: Ann Rheum Dis. 2016 Feb;75(2):473.

19.

2015 Gout Classification Criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Neogi T, Jansen TL, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJ, Lioté F, Naden RP, Nuki G, Ogdie A, Perez-Ruiz F, Saag K, Singh JA, Sundy JS, Tausche AK, Vazquez-Mellado J, Yarows SA, Taylor WJ.

Arthritis Rheumatol. 2015 Oct;67(10):2557-68. doi: 10.1002/art.39254. Erratum in: Arthritis Rheumatol. 2016 Feb;68(2):515. Vaquez-Mellado, Janitzia [corrected to Vazquez-Mellado, Janitzia].

20.

Bisphosphonates and glucocorticoid-induced osteoporosis: cons.

Lems WF, Saag K.

Endocrine. 2015 Aug;49(3):628-34. doi: 10.1007/s12020-015-0639-1. Epub 2015 Jun 4. Review.

Supplemental Content

Loading ...
Support Center